Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke

Launched by CAN THO STROKE INTERNATIONAL SERVICES HOSPITAL · Sep 21, 2021

Keywords

ClinConnect Summary

In symptomatic ischemic stroke due to intracranial large severe stenosis or occlusive artery, the choice for treatment has remained controversial after results of the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial because it demonstrated that the efficacy of medical treatment was superior to intracranial stenting in the low risk of periprocedural stroke or death. However, this conclusion has influenced the role of intracranial stenting in the ischemic stroke treatment and recovery time for a long time because of the unproper patient selection ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Evidence of intracranial large severe stenosis or occlusive artery in angiography.
• • Absence of intracranial hemorrhage.
• • Premorbid mRS score is ≤ 3.
• • Recurrent stroke in the target territory during the medical treatment for ischemic stroke prevention.
• Exclusion Criteria:
• • Tandem lesion.
• • Loss to follow-up after discharge.
• • A severe or fatal combined illness before acute ischemic stroke.
• • Progressive neurologic deficit within 7 days after acute ischemic stroke.
• • Large middle cerebral artery infarct within 30 days after acute ischemic stroke.